Clinical trials: Hereditary Spherocytosis
Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia
Pyruvate Kinase Deficiency Natural History Study
The purpose of this study is to describe the range and incidence of symptoms, treatments, and complications related to pyruvate kinase deficiency (PKD).
- Trial name
- PKD NHS (NCT02053480)
- Where
- 30 sites in United States, Canada and 4 more
- Volunteers
- 254 people
- Sponsor
- Boston Children's Hospital
Hereditary, Hemolysis
Hemolysis in Patients With Hereditary Spherocytosis (HS)
In the present study the investigators are going to explore the oxidative status of HS-RBC and its contribution to hemolysis
- Trial name
- NCT01201174
- Testing
- fermented papaya preparation (FPP)
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center
Hereditary Spherocytosis
The Dallas Hereditary Spherocytosis Cohort Study
The purpose of this study is to 1. better characterize the short term and long term natural history of hereditary spherocytosis (HS) including diagnosis, complications, and indications for and response to splenectomy 2.
- Trial name
- NCT01141621
- Volunteers
- 55 people
- Sponsor
- University of Texas Southwestern Medical Center
Sickle Cell Disease, Thalassaemia
Integrative Diagnosis for SCD and Other RADs
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
- Conditions
- Sickle Cell Disease, Thalassaemia, Congenital Dyserythropoietic Anemia (CDA), Enzyme Disorder; Anemia
- Trial name
- INTEGRA (NCT07206095)
- Testing
- Analysis of genetic modifiers, Disease phenotyping
- Where
- 9 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hereditary Spherocytosis, Hemolytic Anemia
New CBC Parameters in Diagnosis of Hereditary Spherocytosis
This cross-sectional study aims to evaluate the diagnostic performance of selected automated complete blood count-derived erythrocytic and reticulocytic parameters in children with hereditary spherocytosis.
- Trial name
- NCT07842718
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hemoglobinopathies, Sickle Cell Disease
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk…
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia, Sickle Beta Thalassemia
- Trial name
- NCT06831799
- Testing
- Non applicable, is a patient registry
- Where
- Spain
- Volunteers
- 684 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hereditary Spherocytosis
Hereditary Spherocytosis and Vascular Function
Background : Patients with hereditary spherocytosis (HS) are characterized by increased red blood cell (RBC) fragility and a loss of RBC deformability.
- Trial name
- VASCUSPHERO (NCT04451785)
- Testing
- blood sample, Pulse wave velocity
- Where
- 2 sites in France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
Single Incision Versus Standard Laparoscopic Splenectomy
This is a prospective trial of single incision versus standard 4-port laparoscopic splenectomy. The hypothesis is that there may be a difference in wound infection rates, operative time, doses of analgesics post-operatively, and…
- Trial name
- NCT01276561
- Testing
- Single Incision Splenectomy, Laparoscopic Splenectomy
- Where
- United States
- Sponsor
- Children's Mercy Hospital Kansas City
Patients With Thalassemia Intermedia,, Congenital Dyserythropoietic Anemia Type I
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis
Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin…
- Trial name
- GDF 15 (NCT01201135)
- Volunteers
- 80 people
- Sponsor
- Wolfson Medical Center